Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 206 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo 600mg Clear all
Completed Phase 3 Interventional

Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

NCT00135109
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A New Paradigm for Vitamin D Sufficiency

NCT02969850
View directory record Official record
Conditions
New Biomarkers for Measuring Vitamin D Level
Interventions
Vitamin D Supplementation, Placebo, Calcium
Dietary Supplement · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Anti-LPS Antibody Treatment for Pediatric NAFLD

NCT03042767
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
IMM-124E, Placebo
Biological · Other
Lead sponsor
Miriam Vos, MD
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 30, 2026, 5:54 AM EDT
Terminated Phase 2 Interventional Results available

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

NCT02415595
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-955176, EFV, TDF/FTC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Beverly Hills, California • Los Angeles, California • DeLand, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 2 Interventional

Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty

NCT05283486
View directory record Official record
Conditions
Sarcopenia, Frailty, Aging
Interventions
MYMD-1 600MG, MYMD-1 750mg, MYMD-1 900mg, MYMD-1 1050mg, placebo 600mg, placebo 750mg, placebo 900mg, placebo 1050mg
Drug
Lead sponsor
TNF Pharmaceuticals, Inc.
Industry
Eligibility
65 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Clearwater, Florida • Tampa, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Sep 30, 2026, 5:54 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft

NCT05919745
View directory record Official record
Conditions
Pain, Post Operative, Quality of Life
Interventions
Ibuprofen 600 mg, Placebo, Acetaminophen
Drug
Lead sponsor
Marquette University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Sep 30, 2026, 5:54 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582
View directory record Official record
Conditions
HER2 Positive Breast Cancer
Interventions
Tucatinib, Trastuzumab, Pertuzumab, Combination product: Trastuzumab + Pertuzumab, Placebo
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
76
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Sep 30, 2026, 5:54 AM EDT
Active, not recruiting Phase 1 Interventional

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

NCT05184569
View directory record Official record
Conditions
Semantic Dementia
Interventions
Verdiperstat
Drug
Lead sponsor
Peter Ljubenkov, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 30, 2026, 5:54 AM EDT
Withdrawn Phase 2 Interventional

Development of a Selective ALDH2 Inhibitor to Treat AUD

NCT04311294
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
ANS-6637 Low Dose, ANS-6637 High Dose, Matched Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 30, 2026, 5:54 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

NCT03446807
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Droxidopa, Placebo Oral Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction

NCT05184192
View directory record Official record
Conditions
COVID-19, Olfactory Disorder, Anosmia, Hyposmia, Parosmia
Interventions
Gabapentin gelatin capsules 300mg, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males

NCT03342599
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Alpha Lipoic Acid Supplement, Placebo
Dietary Supplement
Lead sponsor
University of La Verne
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
La Verne, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)

NCT01171794
View directory record Official record
Conditions
Altitude Sickness
Interventions
Ibuprofen, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

NCT06229977
View directory record Official record
Conditions
Bipolar Depression
Interventions
Palmitoylethanolamide (PEA), Placebo, Treatment as Usual (TAU)
Drug
Lead sponsor
Rodrigo Machado-Vieira, MD, PhD, MSc
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Absorption and Digestion Kinetics of Human Metabolites

NCT05017428
View directory record Official record
Conditions
Postprandial Inflammation
Interventions
Spermidine, Nicotinamide, PEA, OEA, Wheat Flour
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 40 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 30, 2026, 5:54 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

CoEnzyme Q10 in Statin Myopathy

NCT01140308
View directory record Official record
Conditions
Statin Myopathy
Interventions
CoEnzyme Q10, Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
20 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study of ORT247 in Healthy Volunteers

NCT06769620
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
ORT247, Placebo
Drug
Lead sponsor
Orthogonal Neuroscience Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

NCT03752307
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Isoxsuprine Hydrochloride, Placebo, Corticosteroid
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients

NCT01134198
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Mifepristone, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

PTG-100 for Patients With Celiac Disease

NCT04524221
View directory record Official record
Conditions
Celiac Disease
Interventions
PTG-100, Placebo
Drug
Lead sponsor
Nielsen Fernandez-Becker
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Psychosis and Agitation in Alzheimer's Disease

NCT02129348
View directory record Official record
Conditions
Alzheimer's Disease, Psychosis, Agitation
Interventions
Lithium, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Miami, Florida • Belmont, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 30, 2026, 5:54 AM EDT
Terminated Phase 3 Interventional

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

NCT00836069
View directory record Official record
Conditions
Anxiety Disorders
Interventions
No drug name provided by Sponsor; drug referenced as PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 30, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers

NCT04527718
View directory record Official record
Conditions
Healthy
Interventions
Placebo, 611
Drug
Lead sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Sep 30, 2026, 5:54 AM EDT